

DOCKET NO.: ISIS0171-100 (ISPH-0794)**PATENT****REMARKS**

Claims 17 and 32-38 are pending in the instant patent application. Applicants herewith have amended claim 17 and noted that claims 32-38 are withdrawn from consideration. In addition, Applicants have added claims 39-42, support for which can be found throughout the specification and claims as originally filed. For example support can be found on page 5, line 26-29, page 19, lines 8-14, and page 23, lines 8-18. No new matter has been added.

With the entry of the instant amendment, claims 17, 39-42 are pending and claims 32-38 are withdrawn.

Restriction To A Single Nucleotide Sequence

The Examiner has required that Applicants elect one activity enhancing sequence motif and one activity decreasing sequence motif. In compliance with this requirement, Applicants hereby elect 5'-CCAC-3' as the activity enhancing sequence motif and 5'-GGGG-3' as the activity-decreasing sequence motif. Applicants hereby reserve the right to pursue unelected subject matter in continuing applications claiming priority benefit to the instant patent application.

Applicants submit that the present response is complete and complies with the requirements of 35 U.S.C. §121. Applicants do not believe that a fee is required with the instant submission; however, in the event of a deficiency the Commissioner is permitted to charge, Isis Pharmaceuticals, Inc., Deposit Account No. 50-0252, referencing Attorney Docket No. ISPH-0794.

Respectfully submitted,



Jason D. Ferrone, Esq.
Registration No. 52,887

Date: June 21, 2006

Isis Pharmaceuticals, Inc.
1896 Rutherford Road
Carlsbad, CA 92008
(760) 603-4631